The U.S. FDA approved an expanded 26-week efficacy claim for Zimmer Biomet Holdings Inc.'s Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.
US FDA approves expanded efficacy claim for Zimmer's knee pain drug
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help